SR One, a transatlantic life sciences investment firm, has closed its Fund II at $600 million, which exceeds its target of $500 million. This is the second fund since SR One spun out from GlaxoSmithKline (GSK) in 2020 to form a fully independent investment firm.
With Fund II, SR One will continue to invest in biotech companies that have the potential to address significant gaps in the current treatment landscape. It focuses on companies that translate innovative science into the next generation of novel medicines.
“We received an incredible response to the fund and are grateful to our limited partners for their continued support and confidence in our team,” said Simeon George, MD, Co-Founder and Chief Executive Officer, SR One. “SR One’s model is built upon active collaboration and our ability to roll up our sleeves and help build value through multiple inflection points. We seek to partner with entrepreneurs building elite biotechnology companies, and we look forward to the potential development of new medicines for patients that Fund II may help bring to the market.”
“We have built a team of seasoned investors and venture partners who I believe are well positioned to continue SR One’s history of productive investment,” said Rajeev Dadoo, PhD, Managing Partner, SR One. “With Fund II, we hope to continue to apply our tried and tested partnership model in an effort to benefit the companies in which we invest and, ultimately, the patients and families that they serve.”
Backs companies developing next-gen medicines
Headquartered in San Francisco, SR One has offices in California, Philadelphia, and London. Its mission is to translate innovative technologies and scientific discoveries into next-generation medicines with the potential to benefit patients with significant unmet medical needs.
SR One focuses on investing in early-stage healthcare and life science companies with a particular emphasis on biotechnology, pharmaceuticals, and medical devices. Its investment strategy focuses on providing financial and direct operational support to help its portfolio companies advance programs through value-generating inflection points.
The diverse investor base of existing and new limited partners includes endowments, foundations, pharmaceutical companies, pension funds, sovereign wealth funds, and family offices. To date, SR One has raised over $1 billion and founded and/or invested in over 20 companies.
